Routine 3D treatment planning: Opportunities, challenges, and hazards

Lawrence B. Marks, Gunilla Bentel, Kim Light, Su Min Zhou, Gregory Sibley, Mitchell Anscher

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Three-dimensional (3D) treatment planning refers to the use of software and hardware tools to design and implement more accurate and conformai radiation therapy. This is a major advance in oncology that should lead to the reduction of treatment-associated morbidity and facilitate safe dose escalation for many tumor sites. This technology affords the incorporation of physiologic and anatomic information into the treatment planning process, further enhancing our ability to improve the therapeutic ratio. However, as with any new technology, care must be taken when applying it in the clinic. The introduction of 3D planning presents new challenges to existing quality assurance systems. These need to be addressed to maintain patient safety. Based on our experience with over 1,500 patients treated at Duke University, the benefits, challenges, and hazards of routine 3D treatment planning are discussed.

Original languageEnglish (US)
Pages (from-to)1191-1201
Number of pages11
JournalONCOLOGY
Volume14
Issue number8
StatePublished - Dec 1 2000

Fingerprint

Technology
Therapeutics
Patient Safety
Radiotherapy
Software
Morbidity
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Marks, L. B., Bentel, G., Light, K., Zhou, S. M., Sibley, G., & Anscher, M. (2000). Routine 3D treatment planning: Opportunities, challenges, and hazards. ONCOLOGY, 14(8), 1191-1201.

Routine 3D treatment planning : Opportunities, challenges, and hazards. / Marks, Lawrence B.; Bentel, Gunilla; Light, Kim; Zhou, Su Min; Sibley, Gregory; Anscher, Mitchell.

In: ONCOLOGY, Vol. 14, No. 8, 01.12.2000, p. 1191-1201.

Research output: Contribution to journalArticle

Marks, LB, Bentel, G, Light, K, Zhou, SM, Sibley, G & Anscher, M 2000, 'Routine 3D treatment planning: Opportunities, challenges, and hazards', ONCOLOGY, vol. 14, no. 8, pp. 1191-1201.
Marks LB, Bentel G, Light K, Zhou SM, Sibley G, Anscher M. Routine 3D treatment planning: Opportunities, challenges, and hazards. ONCOLOGY. 2000 Dec 1;14(8):1191-1201.
Marks, Lawrence B. ; Bentel, Gunilla ; Light, Kim ; Zhou, Su Min ; Sibley, Gregory ; Anscher, Mitchell. / Routine 3D treatment planning : Opportunities, challenges, and hazards. In: ONCOLOGY. 2000 ; Vol. 14, No. 8. pp. 1191-1201.
@article{fbbffdc8d6e24d96ac6179da7421d303,
title = "Routine 3D treatment planning: Opportunities, challenges, and hazards",
abstract = "Three-dimensional (3D) treatment planning refers to the use of software and hardware tools to design and implement more accurate and conformai radiation therapy. This is a major advance in oncology that should lead to the reduction of treatment-associated morbidity and facilitate safe dose escalation for many tumor sites. This technology affords the incorporation of physiologic and anatomic information into the treatment planning process, further enhancing our ability to improve the therapeutic ratio. However, as with any new technology, care must be taken when applying it in the clinic. The introduction of 3D planning presents new challenges to existing quality assurance systems. These need to be addressed to maintain patient safety. Based on our experience with over 1,500 patients treated at Duke University, the benefits, challenges, and hazards of routine 3D treatment planning are discussed.",
author = "Marks, {Lawrence B.} and Gunilla Bentel and Kim Light and Zhou, {Su Min} and Gregory Sibley and Mitchell Anscher",
year = "2000",
month = "12",
day = "1",
language = "English (US)",
volume = "14",
pages = "1191--1201",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "8",

}

TY - JOUR

T1 - Routine 3D treatment planning

T2 - Opportunities, challenges, and hazards

AU - Marks, Lawrence B.

AU - Bentel, Gunilla

AU - Light, Kim

AU - Zhou, Su Min

AU - Sibley, Gregory

AU - Anscher, Mitchell

PY - 2000/12/1

Y1 - 2000/12/1

N2 - Three-dimensional (3D) treatment planning refers to the use of software and hardware tools to design and implement more accurate and conformai radiation therapy. This is a major advance in oncology that should lead to the reduction of treatment-associated morbidity and facilitate safe dose escalation for many tumor sites. This technology affords the incorporation of physiologic and anatomic information into the treatment planning process, further enhancing our ability to improve the therapeutic ratio. However, as with any new technology, care must be taken when applying it in the clinic. The introduction of 3D planning presents new challenges to existing quality assurance systems. These need to be addressed to maintain patient safety. Based on our experience with over 1,500 patients treated at Duke University, the benefits, challenges, and hazards of routine 3D treatment planning are discussed.

AB - Three-dimensional (3D) treatment planning refers to the use of software and hardware tools to design and implement more accurate and conformai radiation therapy. This is a major advance in oncology that should lead to the reduction of treatment-associated morbidity and facilitate safe dose escalation for many tumor sites. This technology affords the incorporation of physiologic and anatomic information into the treatment planning process, further enhancing our ability to improve the therapeutic ratio. However, as with any new technology, care must be taken when applying it in the clinic. The introduction of 3D planning presents new challenges to existing quality assurance systems. These need to be addressed to maintain patient safety. Based on our experience with over 1,500 patients treated at Duke University, the benefits, challenges, and hazards of routine 3D treatment planning are discussed.

UR - http://www.scopus.com/inward/record.url?scp=0034242985&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034242985&partnerID=8YFLogxK

M3 - Article

C2 - 10989828

AN - SCOPUS:0034242985

VL - 14

SP - 1191

EP - 1201

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 8

ER -